Summary & Overview
HCPCS J0717: Certolizumab Pegol Injection, 1 mg
HCPCS Level II code J0717 denotes certolizumab pegol injectable, billed by milligram for doses administered under direct physician supervision rather than self-administration. This biologic is used for inflammatory and autoimmune conditions and is billed as a drug administration service in outpatient infusion or clinic settings. Nationally, accurate coding for high-cost biologics like certolizumab pegol affects provider reimbursement, payer medical-management workflows, and patient access to specialty therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how J0717 is structured, common sites of service, and the billing context for physician-supervised administration. The publication also summarizes typical modifiers and service-line considerations, payer coverage patterns, and where to look for policy and benefit determination details.
The content provides clinical and billing context for coding teams, revenue cycle staff, and policy analysts: what the code represents, typical billing scenarios, and practical documentation touchpoints. Data not available in the input are noted where applicable; the focus remains on national implications rather than state-specific rules.
Billing Code Overview
HCPCS Level II code J0717 represents the injectable biologic certolizumab pegol, billed per 1 mg unit. The code description specifies use when the drug is administered under the direct supervision of a physician and not for self-administered dosing.
Service type: Drug administration (injectable biologic), physician-supervised
Typical site of service: Outpatient infusion or injection setting under physician supervision, such as hospital outpatient departments, physician offices, or clinic infusion suites.
Clinical & Coding Specifications
Clinical Context
A 54-year-old patient with moderate to severe rheumatoid arthritis receives a clinic-administered biologic injection of certolizumab pegol. The patient presents to a physician office or hospital outpatient infusion clinic for a scheduled subcutaneous injection under the direct supervision of the prescribing physician because the payer requires clinician administration documentation. The workflow includes verification of patient identity and allergy history, review of recent labs and infection screening, premedication if indicated, preparation of the appropriate dose from the supplied vial or syringe, administration of the injectible medication by a licensed clinician, monitoring for immediate adverse reaction for 15–30 minutes, and documentation of lot number, dose, route, site, and supervision. Billing uses HCPCS Level II code J0717 per milligram with total milligrams administered reported as units. Typical sites of service are an ambulatory physician office, hospital outpatient department, or infusion center when the drug is not self-administered by the patient.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | When part of a multi-dose vial is discarded after withdrawal of the billed amount |